Vivo Capital’s Matinas BioPharma MTNB Stock Holding History

Vivo Capital’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-129,032	Closed	-$8.77M	–	64
2020 Q4	$8.77M	Sell	129,032 -96,554	-43%	-$4.47M	0.39%	43
2020 Q3	$8.64M	Hold	225,586	–	–	0.5%	42
2020 Q2	$8.72M	Hold	225,586	–	–	0.63%	34
2020 Q1	$6.77M	Buy	+225,586	New	+$13.6M	0.61%	38
2019 Q3	–	Sell	-136,364	Closed	-$5.84M	–	23
2019 Q2	$5.84M	Hold	136,364	–	–	0.55%	35
2019 Q1	$7.43M	Buy	+136,364	New	+$7.34M	0.74%	35

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vivo Capital's MTNB Position: Q1 2021 in Review

Vivo Capital sold out of Matinas BioPharma (MTNB) in Q1 2021, closing a stake of 129,032 shares — an estimated $8.77M sold.

Vivo Capital first reported a position in MTNB in Q1 2019 and held it in 6 quarters. The position peaked at $8.77M in Q4 2020. 80 funds tracked by Wall St. Rank hold MTNB as of Q1 2021.

Vivo Capital reported no remaining Matinas BioPharma position as of Q1 2021 after selling out during the quarter.
Vivo Capital sold 129,032 Matinas BioPharma shares in Q1 2021, an estimated $8.77M.
Vivo Capital first reported a position in Matinas BioPharma in Q1 2019 and held it in 6 quarters.
Vivo Capital's Matinas BioPharma position peaked at $8.77M in Q4 2020.
80 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2021.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.